Nivolumab Plus Ipilimumab Demonstrates Superiority Over Chemotherapy in MSI-H/dMMR Metastatic Colorectal Cancer
• The CheckMate 8HW trial demonstrated that nivolumab plus ipilimumab significantly improved progression-free survival compared to chemotherapy in previously untreated patients with MSI-H/dMMR metastatic colorectal cancer.
• The immunotherapy combination reduced the risk of disease progression or death by 79% compared to chemotherapy, with a hazard ratio of 0.21 (P < .0001).
• At 24 months, the progression-free survival rate was 72% with nivolumab/ipilimumab versus 14% with chemotherapy, indicating a substantial and sustained benefit.
• The safety profile of nivolumab plus ipilimumab was distinct from chemotherapy, with fewer grade 3/4 treatment-related adverse events.
© Copyright 2025. All Rights Reserved by MedPath